Equities Analysts Offer Predictions for IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Wedbush lowered their FY2025 earnings estimates for IDEAYA Biosciences in a research note issued on Tuesday, November 4th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($1.38) for the year, down from their prior forecast of ($1.29). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q4 2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($1.11) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($4.00) EPS, FY2027 earnings at ($3.81) EPS, FY2028 earnings at ($3.46) EPS and FY2029 earnings at ($1.11) EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to analysts’ expectations of $59.98 million.

IDYA has been the topic of a number of other reports. Guggenheim began coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 18th. They set a “buy” rating and a $50.00 price target on the stock. Barclays assumed coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set an “overweight” rating and a $40.00 target price on the stock. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a “buy” rating for the company. The Goldman Sachs Group upped their price target on IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Wednesday, October 8th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $45.36.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $29.85 on Friday. The business’s fifty day moving average price is $27.40 and its 200 day moving average price is $23.63. The firm has a market capitalization of $2.62 billion, a PE ratio of -16.05 and a beta of 0.14. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $33.64.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of large investors have recently bought and sold shares of IDYA. Vanguard Group Inc. increased its position in IDEAYA Biosciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock worth $83,417,000 after buying an additional 14,535 shares in the last quarter. Geode Capital Management LLC raised its stake in IDEAYA Biosciences by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock valued at $44,424,000 after purchasing an additional 33,286 shares during the last quarter. Fiera Capital Corp lifted its holdings in IDEAYA Biosciences by 26.6% in the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock valued at $32,208,000 after purchasing an additional 322,404 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in IDEAYA Biosciences by 4.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock valued at $26,025,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Candriam S.C.A. boosted its stake in shares of IDEAYA Biosciences by 10.8% during the 3rd quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock worth $27,563,000 after purchasing an additional 98,567 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.